Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PER2 | O15055 | 7/20 | 0.38 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11207217 | 0.80 | — | — | |
| SCHEMBL16830251 | 0.79 | ALDH1A1 (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16830249 | 0.77 | MAPT (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17946144 | 0.75 | — | — | |
| SCHEMBL2379257 | 0.75 | — | — | |
| SCHEMBL7621988 | 0.74 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9851987 | 0.74 | CYP3A4 (0.33) | CYP3A4ALDH1A1 | |
| SCHEMBL9851985 | 0.74 | CYP3A4 (0.33) | CYP3A4ALDH1A1 | |
| SCHEMBL9851999 | 0.74 | FAAH (0.36) | PER2MAPTSRD5A1SRD5A2AR | |
| SCHEMBL9852001 | 0.74 | FAAH (0.36) | PER2MAPTSRD5A1SRD5A2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016135268-A1 | METHOD FOR PREPARING A CHEMICAL COMPOUND USING A RUTHENIUM METAL CATALYST ON A ZIRCONIUM OXIDE SUPPORT IN THE PRESENCE OF A CONTAMINANT | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2016-09-01 | — | — | WO | claimed |
| WO-2015026234-A1 | SUPPORTED METAL NANOPARTICLE-BASED CATALYST FOR THE HYDROGENATION OF A LEVULINIC ACID SOURCE | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2015-02-26 | — | — | WO | claimed |
| US-7465813-B2 | Process for making 5-methyl-N-alkyl-2-pyrrolidone from alkyl amine(s) and levulinic acid | E. I. DU PONT DE NEMOURS + COMPANY (US) | 2008-12-16 | — | — | US | claimed |
| US-20060247444-A1 | Process for making 5-methyl-N-alkyl-2-pyrrolidone from alkyl amine(s) and levulinic acid | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-02 | — | — | US | claimed |
| US-20060247443-A1 | Process for making 5-methyl -N-alkyl-2-pyrrolidone from alkyl amines and alkyl levulinate esters | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-02 | — | — | US | claimed |
| EP-1663967-A1 | PROCESS FOR CONVERTING a-ANGELICA LACTONE TO 5-METHYL-N-ALKYL -2-PYRROLIDONE USING ALKYL AMINES | E. I. du Pont de Nemours and Company (US) | 2006-06-07 | — | — | EP | claimed |
| US-7030249-B2 | Process for converting α-angelica lactone to 5-methyl-N-alkyl-2-pyrrolidone using alkyl amines | E. I. UPONT DE NEMOURS AND COMPANY (US) | 2006-04-18 | — | — | US | claimed |
| WO-2005026115-A1 | PROCESS FOR CONVERTING α-ANGELICA LACTONE TO 5-METHYL-N-ALKYL-2-PYRROLIDONE USING ALKYL AMINES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050054861-A1 | Process for converting alpha-angelica lactone to 5-methyl-N-alkyl-2-pyrrolidone using alkyl amines | E. I. DU PONT DE NEMOURS AND COMPANY | 2005-03-10 | — | — | US | claimed |
| US-6841520-B2 | Production of 5-methyl-N-(methyl aryl)-2-pyrrolidone, 5-methyl-N-(methyl cycloalkyl)-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid with cyano compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-01-11 | — | — | US | claimed |
| US-6818593-B2 | Production of 5-Methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid with nitro compounds | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-11-16 | — | — | US | claimed |
| CN-114934082-B | Method for synthesizing (S) -5-methyl-2-pyrrolidone by continuous flow biocatalysis | 华东理工大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-114686451-B | Amine dehydrogenase mutant and application thereof in preparation of (S) -5-methyl-2-pyrrolidone | 华东理工大学 | 2024-03-08 | — | — | CN | disclosed |
| CN-114934082-A | Method for continuous flow biocatalytic synthesis of (S) -5-methyl-2-pyrrolidone | 华东理工大学 | 2022-08-23 | — | — | CN | disclosed |
| CN-114686451-A | Amine dehydrogenase mutant and application thereof in preparation of (S) -5-methyl-2-pyrrolidone | 华东理工大学 | 2022-07-01 | — | — | CN | disclosed |
| US-20040192936-A1 | PRODUCTION OF N-ARYL-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYL NITRO COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-09-30 | — | — | US | disclosed |
| US-6743819-B1 | METAL CATALYST | E. I. DU PONTE DE NEMOURS AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247444-A1 | Process for making 5-methyl-N-alkyl-2-pyrrolidone from alkyl amine(s) and levulinic acid | GRIK5, ALDH18A1, ALAD | CHRM2 2492/4885CHRM4 2929/4885CHRM5 571/4885 |
| US-20060247443-A1 | Process for making 5-methyl -N-alkyl-2-pyrrolidone from alkyl amines and alkyl levulinate esters | ALDH18A1, ADH5, PRMT5 | CHRM2 2385/4885CHRM4 2125/4885CHRM5 506/4885 |
| US-20050054861-A1 | Process for converting alpha-angelica lactone to 5-methyl-N-alkyl-2-pyrrolidone using alkyl amines | DNMT1, TET2, PRMT5 | CHRM2 2650/4885CHRM4 2984/4885CHRM5 1576/4885 |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | CHRM2 501/4885CHRM4 424/4885CHRM5 337/4885 |
| US-20040192936-A1 | PRODUCTION OF N-ARYL-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYL NITRO COMPOUNDS | NIT2, NANS, ASNS | CHRM2 3392/4885CHRM4 3408/4885CHRM5 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.